Article Text

other Versions

PDF
Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia
  1. Magda Gharbiya,
  2. Filippo Cruciani,
  3. Francesco Parisi,
  4. Giovanni Cuozzo,
  5. Simona Altimari,
  6. Solmaz Abdolrahimzadeh
  1. Department of Ophthalmology, Sapienza University, Umberto I Hospital, Rome, Italy
  1. Correspondence to Dr Magda Gharbiya, Department of Ophthalmology, Sapienza University – Umberto I Hospital, 155 Viale del Policlinico, 00161 Rome, Italy; magda.gharbiya{at}tiscali.it

Abstract

Aim To evaluate the long-term results and prognostic factors of intravitreal bevacizumab (IVB) for myopic choroidal neovascularisation (mCNV).

Methods Thirty-two eyes of 30 patients with mCNV were included in a prospective case series. Treatment consisted of three monthly 1.25 mg IVB injections. Best corrected visual acuity (BCVA) and CNV area were compared before and after treatment. Prognostic factors included in the regression analyses were age, axial length, baseline BCVA, pretreatment CNV area, CNV location and peripapillary atrophy area.

Results Results were evaluated at 2 years for 32 eyes and at 3 years for 27 eyes. Mean (±SD) baseline BCVA had improved significantly from 30.1 (±15.6) letters to 45.4 (±13.0) letters at 3 years (p<0.0001), with a better outcome in eyes with juxtafoveal CNV (40.4 ± 13.5 vs. 54.0 ± 5.8, p=0.001). Baseline BCVA correlated positively with final BCVA (β= 0.560, p=0.001), while age showed a negative correlation (β= −0.399, p=0.01). CNV area decreased from 0.63 (±0.71) mm2 at baseline to 0.40 (±0.57) mm2 at 3 years (p<0.0001). Peripapillary atrophy area was the only significant contributing determinant for re-treatment (OR 1.20, 95% CI 1.01 to 1.42, p=0.04).

Conclusions A regimen of three monthly IVB injections yielded effective and sustained results in the treatment of mCNV at 3 years of follow-up. Initial BCVA and age were the factors that correlated independently with BCVA outcome.

  • Myopic choroidal neovascularisation
  • bevacizumab
  • pathological myopia
  • anti-vascular endothelial growth factor
  • prognostic factors
  • retina
  • angiogenesis
  • clinical trial
  • degeneration
  • diagnostic tests/investigation
  • drugs
  • cornea
  • macula
  • treatment lasers
  • vision

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Provided by the local ethics committee of the Sapienza University of Rome.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Michelle English